Mefunidone alleviates silica-induced inflammation and fibrosis by inhibiting the TLR4-NF-κB/MAPK pathway and attenuating pyroptosis in murine macrophages

• Published in: Biomedicine & pharmacotherapy Vol. 178; p. 117216
• Main Authors: Long, Lingzhi, Dai, Xiaoqing, Yao, Tingting, Zhang, Xiangyu, Jiang, Guoliang, Cheng, Xiaoyun, Jiang, Mao, He, Yijun, Peng, Zhangzhe, Hu, Gaoyun, Tao, Lijian, Meng, Jie
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-09-2024; Elsevier
• Subjects: Animals; Disease Models, Animal; Fibrosis; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Inflammation - pathology; Macrophages - drug effects; Macrophages - metabolism; Male; MAP Kinase Signaling System - drug effects; Mefunidone; Mice; Mice, Inbred C57BL; NF-kappa B - metabolism; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - drug therapy; Pulmonary Fibrosis - metabolism; Pulmonary Fibrosis - pathology; Pyridones - pharmacology; Pyroptosis; Pyroptosis - drug effects; Signal Transduction - drug effects; Silicon Dioxide - toxicity; Silicosis; Silicosis - drug therapy; Silicosis - metabolism; Silicosis - pathology; Toll-Like Receptor 4 - metabolism; L929 mouse fibroblasts; JNK; FN; SPF; MFD; F4/80; MLE-12 cells; CD11c; MyD88; CD11b; IκB; DMEM; NF-κB; α-SMA; IL-12β; ANOVA; CCL2; NLRP3; KEGG; SiO2; Silicosis; PBS; GSDMD; IBMDMs; Pyroptosis; H&E; BALF; qRT-PCR; IKK; DAPI; Inflammation; MAPK; IL-1β; EMT; IL-6; IL-10; TLR1; RPMI 1640 Medium; MEM; TNF-α; Nano-SiO2; TRAF6; Mefunidone; Fibrosis; IL-8Rα; ERK; ELISA
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.117216

Silicosis is the most common and severe type of pneumoconiosis, imposing a substantial disease burden and economic loss on patients and society. The pathogenesis and key targets of silicosis are not yet clear, and there are currently no effective treatments available. Therefore, we conducted research on mefunidone (MFD), a novel antifibrotic drug, to explore its efficacy and mechanism of action in murine silicosis.
Acute 7-day and chronic 28-day silicosis models were constructed in C57BL/6J mice by the intratracheal instillation of silica and subsequently treated with MFD to assess its therapeutic potential. The effects of MFD on silica-induced inflammation, pyroptosis, and fibrosis were further investigated using immortalized mouse bone marrow-derived macrophages (iBMDMs).
In the 7-day silica-exposed mouse models, MFD treatment significantly alleviated pulmonary inflammation and notably reduced macrophage infiltration into the lung tissue. RNA-sequencing analysis of silica-induced iBMDMs followed by gene set enrichment analysis revealed that MFD profoundly influenced cytokine-cytokine receptor interactions, chemokine signaling, and the toll-like receptor signaling pathways. MFD treatment also markedly reduced the secretion of inflammatory cytokines and chemokines from silica-exposed iBMDMs. Moreover, MFD effectively downregulated the activation of the TLR4-NF-κB/MAPK signaling pathway induced by silica and mitigated the upregulation of pyroptosis markers. Additionally, MFD treatment significantly suppressed the activation of fibroblasts and alveolar epithelial cells co-cultured with silica-exposed mouse macrophages. Ultimately, in the 28-day silica-exposed mouse models, MFD administration led to a substantial reduction in the severity of pulmonary fibrosis.
MFD mitigates silica-induced pulmonary inflammation and fibrosis in mice by suppressing the TLR4-NF-κB/MAPK signaling pathway and reducing pyroptotic responses in macrophages. MFD could potentially emerge as a novel therapeutic agent for the treatment of silicosis.
[Display omitted]